Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track VERU with free AI briefings, catalyst countdowns, and dilution alerts.

VERU · Veru Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar: financing pressure. About 10.0 months of cash at its recent burn rate (Jun 30, 2026 balance sheet), an at-the-market (ATM) program filed Jul 2, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 to 12 months of cash, 35% sold new shares within three months and 67% were lower 60 trading days later (median -12%). How we know
$23.9M Cash on Hand
10mo Cash Runway
9.7% Short Interest
$25.67 Analyst Target (3)
Follow VERU by email Get an email when VERU reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about VERU, unsubscribe in one click. Privacy

📣 What VERU Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Enobosarm Metastatic Breast Cancer Phase 3 · NCT04869943 Terminated
Sabizabulin (VERU-111) SARS-CoV Infection Phase 3 · NCT04842747 Completed
Sacituzumab Govitecan Metastatic Triple Negative Breast Cancer Phase 2 · NCT05008510 Withdrawn
Semaglutide (Wegovy) weekly injection Obesity & Overweight Phase 2 · NCT07446998 Active not recruiting
GnRH Antagonist VERU-100 Advanced Prostate Adenocarcinoma Phase 1/2 · NCT04843319 Terminated
Zuclomiphene Citrate Prostate Cancer Metastatic Phase 2 · NCT03646162 Completed

Also used in these trials (approved or third-party drugs, not VERU's own candidates): Abemaciclib, Enzalutamide, Exemestane, Oral Semaglutide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

VERU holds $23.9M in cash and short-term investments (as of Jun 30, 2026) and burns about $7.2M/quarter from operations, an estimated runway of 10 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 77 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VERU files for a raise →

👥 Who Owns VERU

Insiders 1.5% Institutions 20.9% Public and other holders 77.6%
HolderTypeShares% of sharesAs of
Alyeska Investment Group, L.P. Institution (13G, 5%+) 1,588,982 9.32% 2025-12-31
Vanguard Capital Management LLC Institution (13F) 690,105 4.05% 2026-09-30
Michael L Rankowitz
Director · +220,000 options
Insider 250,000 1.47% 2025-02-18
Renaissance Technologies, LLC Institution (13F) 207,450 1.22% 2026-09-30
Oppenheimer & Co Inc Institution (13F) 196,547 1.15% 2026-09-30
Geode Capital Management, LLC Institution (13F) 194,231 1.14% 2026-09-30
Blackrock Inc. Institution (13F) 164,802 0.97% 2026-09-30
Summit Financial, LLC Institution (13F) 140,955 0.83% 2026-09-30
GSA Capital Partners LLP Institution (13F) 129,431 0.76% 2026-09-30
Schonfeld Strategic Advisors Llc Institution (13F) 88,798 0.52% 2026-09-30
Raymond James Financial, Inc. Institution (13F) 81,872 0.48% 2026-09-30
Vanguard Fiduciary Trust Co Institution (13F) 81,230 0.48% 2026-09-30

Share count 17,050,320 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-08-13
filed 2026-08-17
BARNETTE K GARY
Purchase (P) 1,800 $2.69 2,300
2026-05-04
filed 2026-05-06
Greco Michele
Option award (A) 164,000 – –
2026-05-04
filed 2026-05-06
Lu Lucy
Option award (A) 104,000 – –
2026-05-04
filed 2026-05-06
Rankowitz Michael L
Option award (A) 100,000 – –
2026-05-04
filed 2026-05-06
Katzovitz Loren Mark
Option award (A) 102,000 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full VERU picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VERU and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.